Source:http://linkedlifedata.com/resource/pubmed/id/21357293
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2011-4-29
|
pubmed:abstractText |
Disk diffusion testing has recently been standardized by the CLSI, and susceptibility breakpoints have been established for several antifungal compounds. For caspofungin, 5-?g disks are approved, and for micafungin, 10-?g disks are under evaluation. We evaluated the performances of caspofungin and micafungin disk testing using a panel of Candida isolates with and without known FKS echinocandin resistance mechanisms. Disk diffusion and microdilution assays were performed strictly according to CLSI documents M44-A2 and M27-A3. Eighty-nine clinical Candida isolates were included: Candida albicans (20 isolates/10 mutants), C. glabrata (19 isolates/10 mutants), C. dubliniensis (2 isolates/1 mutant), C. krusei (16 isolates/3 mutants), C. parapsilosis (14 isolates/0 mutants), and C. tropicalis (18 isolates/4 mutants). Quality control strains were C. parapsilosis ATCC 22019 and C. krusei ATCC 6258. The correlations between zone diameters and MIC results were good for both compounds, with identical susceptibility classifications for 93.3% of the isolates by applying the current CLSI breakpoints. However, the numbers of fks hot spot mutant isolates misclassified as being susceptible (S) (very major errors [VMEs]) were high (61% for caspofungin [S, ?11 mm] and 93% for micafungin [S, ?14 mm]). Changing the disk diffusion breakpoint to S at ?22 mm significantly improved the discrimination. For caspofungin, 1 VME was detected (a C. tropicalis isolate with an F76S substitution) (3.5%), and for micafungin, 10 VMEs were detected, the majority of which were for C. glabrata (8/10). The broadest separation between zone diameter ranges for wild-type (WT) and mutant isolates was seen for caspofungin (6 to 12 mm versus -4 to 7 mm). In conclusion, caspofungin disk diffusion testing with a modified breakpoint led to excellent separation between WT and mutant isolates for all Candida species.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antifungal Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Echinocandins,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopeptides,
http://linkedlifedata.com/resource/pubmed/chemical/caspofungin,
http://linkedlifedata.com/resource/pubmed/chemical/micafungin
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1098-6596
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1891-5
|
pubmed:dateRevised |
2011-11-1
|
pubmed:meshHeading |
pubmed-meshheading:21357293-Antifungal Agents,
pubmed-meshheading:21357293-Candida,
pubmed-meshheading:21357293-Candida albicans,
pubmed-meshheading:21357293-Candida glabrata,
pubmed-meshheading:21357293-Candida tropicalis,
pubmed-meshheading:21357293-Echinocandins,
pubmed-meshheading:21357293-Lipopeptides,
pubmed-meshheading:21357293-Microbial Sensitivity Tests
|
pubmed:year |
2011
|
pubmed:articleTitle |
Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates.
|
pubmed:affiliation |
Unit of Mycology and Parasitology (43/117), Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. mad@ssi.dk
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|